{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:49:17Z","timestamp":1791510557799,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Dalian Medical Science Research Program","award":["(2023DF016)"],"award-info":[{"award-number":["(2023DF016)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40263-024-01145-5","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:21:26Z","timestamp":1736043686000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"chictr2200059445","registry":"10.18810\/chictr"}],"author":[{"given":"Wen","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-1952","authenticated-orcid":false,"given":"Xiaofei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,5]]},"reference":[{"issue":"1","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00415-017-8490-3","volume":"265","author":"P Seners","year":"2018","unstructured":"Seners P, Baron JC. Revisiting \u201cprogressive stroke\u201d: incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke. J Neurol. 2018;265(1):216\u201325. https:\/\/doi.org\/10.1007\/s00415-017-8490-3.","journal-title":"J Neurol"},{"issue":"2","key":"1145_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1210","volume":"9","author":"X Hou","year":"2019","unstructured":"Hou X, Chen W, Xu H, Zhu Z, Xu Y, Chen H. The rate of early neurological deterioration occurring after thrombolytic therapy: a meta-analysis. Brain Behav. 2019;9(2): e01210. https:\/\/doi.org\/10.1002\/brb3.1210.","journal-title":"Brain Behav"},{"issue":"6","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/neurintsurg-2022-018844","volume":"15","author":"R Bhole","year":"2023","unstructured":"Bhole R, Nouer SS, Tolley EA, Turk A, Siddiqui AH, Alexandrov AV, et al. COMPASS investigators. Predictors of early neurologic deterioration (END) following stroke thrombectomy. J Neurointerv Surg. 2023;15(6):584\u20138. https:\/\/doi.org\/10.1136\/neurintsurg-2022-018844.","journal-title":"J Neurointerv Surg"},{"key":"1145_CR4","doi-asserted-by":"publisher","first-page":"175628642211477","DOI":"10.1177\/17562864221147743","volume":"16","author":"H Liu","year":"2023","unstructured":"Liu H, Liu K, Zhang K, Zong C, Yang H, Li Y, et al. Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study. Ther Adv Neurol Diso. 2023;16:17562864221147744. https:\/\/doi.org\/10.1177\/17562864221147743.","journal-title":"Ther Adv Neurol Diso"},{"issue":"1","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12883-023-03128-3","volume":"23","author":"D Jin","year":"2023","unstructured":"Jin D, Yang J, Zhu H, Wu Y, Liu H, Wang Q, et al. Risk factors for early neurologic deterioration in single small subcortical infarction without carrier artery stenosis: predictors at the early stage. BMC Neurol. 2023;23(1):83. https:\/\/doi.org\/10.1186\/s12883-023-03128-3.","journal-title":"BMC Neurol"},{"issue":"1","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/bc.bc_68_21","volume":"8","author":"A Farooqui","year":"2022","unstructured":"Farooqui A, Albayram MS, Reddy VBN, Nagaraja N. Neurological deterioration and computed tomography perfusion changes with increased time to peak in lacunar stroke. Brain Circ. 2022;8(1):17\u201323. https:\/\/doi.org\/10.4103\/bc.bc_68_21.","journal-title":"Brain Circ"},{"issue":"1","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.24875\/RIC.17002335","volume":"70","author":"R Posadas-Sanchez","year":"2018","unstructured":"Posadas-Sanchez R, Vargas-Alarcon G. Innate immunity in coronary disease. The role of interleukin-12 cytokine family in atherosclerosis. Rev Invest Clin. 2018;70(1):5\u201317. https:\/\/doi.org\/10.24875\/RIC.17002335.","journal-title":"Rev Invest Clin"},{"issue":"18","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"10614","DOI":"10.3390\/ijms231810614","volume":"23","author":"H Pawluk","year":"2022","unstructured":"Pawluk H, Kolodziejska R, Grzesk G, Kozakiewicz M, Wo\u017aniak A, Pawluk M, et al. Selected mediators of inflammation in patients with acute ischemic stroke. Int J Mol Sci. 2022;23(18):10614. https:\/\/doi.org\/10.3390\/ijms231810614.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/antiox10060851","volume":"10","author":"SY Lin","year":"2021","unstructured":"Lin SY, Wang YY, Chang CY, Wu CC, Chen WY, Liao SL, et al. TNF-alpha receptor inhibitor alleviates metabolic and inflammatory changes in a rat model of ischemic stroke. Antioxidants (Basel). 2021;10(6):851. https:\/\/doi.org\/10.3390\/antiox10060851.","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4103\/bc.bc_52_22","volume":"8","author":"F Eren","year":"2022","unstructured":"Eren F, Yilmaz SE. Neuroprotective approach in acute ischemic stroke: a systematic review of clinical and experimental studies. Brain Circ. 2022;8(4):172\u20139. https:\/\/doi.org\/10.4103\/bc.bc_52_22.","journal-title":"Brain Circ"},{"issue":"2","key":"1145_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/bc.bc_70_22","volume":"9","author":"N Yang","year":"2023","unstructured":"Yang N, Lee H, Wu C. Intravenous thrombolysis for acute ischemic stroke: from alteplase to tenecteplase. Brain Circ. 2023;9(2):61\u20133. https:\/\/doi.org\/10.4103\/bc.bc_70_22.","journal-title":"Brain Circ"},{"issue":"3","key":"1145_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023328","volume":"11","author":"E Punch","year":"2022","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc. 2022;11(3): e023328. https:\/\/doi.org\/10.1161\/JAHA.121.023328.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/m15-2994","volume":"164","author":"EP Navarese","year":"2016","unstructured":"Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O\u2019Connor C, Gurbel PA. Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med. 2016;164(9):600\u20137. https:\/\/doi.org\/10.7326\/m15-2994.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","volume":"142","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. 2020;142(4):419\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046320.","journal-title":"Circulation"},{"key":"1145_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1358\/dof.2013.038.07.1981967","volume":"38","author":"E Stein","year":"2013","unstructured":"Stein E, Wasserman SM, Dias C, Scott R, Raal FJ. AMG-145, evolocumab. Drugs Future. 2013;38:451\u20139. https:\/\/doi.org\/10.1358\/dof.2013.038.07.1981967.","journal-title":"Drugs Future"},{"issue":"5","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jamacardio.2016.5395","volume":"2","author":"NR Desai","year":"2017","unstructured":"Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol. 2017;2(5):556\u201360. https:\/\/doi.org\/10.1001\/jamacardio.2016.5395.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"1145_CR17","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1161\/01.str.30.12.2631","volume":"30","author":"A D\u00e1valos","year":"1999","unstructured":"D\u00e1valos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke. 1999;30(12):2631\u20136. https:\/\/doi.org\/10.1161\/01.str.30.12.2631.","journal-title":"Stroke"},{"issue":"25","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/circulationaha.119.043826","volume":"140","author":"JW Jukema","year":"2019","unstructured":"Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, et al. Effect of alirocumab on stroke in ODYSSEY outcomes. Circulation. 2019;140(25):2054\u201362. https:\/\/doi.org\/10.1161\/circulationaha.119.043826.","journal-title":"Circulation"},{"issue":"5","key":"1145_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","volume":"51","author":"RP Giugliano","year":"2020","unstructured":"Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, et al. Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke. 2020;51(5):1546\u201354. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027759.","journal-title":"Stroke"},{"issue":"9","key":"1145_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106294","volume":"9","author":"NA Almontashiri","year":"2014","unstructured":"Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Robert Roberts R, Quyyumi AA, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE. 2014;9(9): e106294. https:\/\/doi.org\/10.1371\/journal.pone.0106294.","journal-title":"PLoS ONE"},{"key":"1145_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1471-2261-14-192","volume":"14","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Liu J, Li S, Sun J, Tang Y, Li JJ. Proprotein convertase subtilisin\/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord. 2014;14:192. https:\/\/doi.org\/10.1186\/1471-2261-14-192.","journal-title":"BMC Cardiovasc Disord"},{"issue":"18","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"New Engl J Med"},{"issue":"16","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New Engl J Med. 2015;372(16):1500\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1500858.","journal-title":"New Engl J Med"},{"issue":"6","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","volume":"2","author":"MJ Koren","year":"2017","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598\u2013607. https:\/\/doi.org\/10.1001\/jamacardio.2017.0747.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaa077","volume":"7","author":"M Zeitouni","year":"2021","unstructured":"Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, et al. 2019 ESC\/EAS guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):324\u201333. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa077.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1145_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.939791","volume":"9","author":"Z Ou","year":"2022","unstructured":"Ou Z, Yu Z, Liang B, Zhao L, Li J, Pang X, et al. Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: a pilot study on Chinese patients. Front Cardiovasc Med. 2022;9: 939791. https:\/\/doi.org\/10.3389\/fcvm.2022.939791.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1145_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.atherosclerosis.2015.08.005","volume":"242","author":"Y Kataoka","year":"2015","unstructured":"Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia SR, et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis. 2015;242(2):490\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.08.005.","journal-title":"Atherosclerosis"},{"issue":"22","key":"1145_CR28","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JPJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384. https:\/\/doi.org\/10.1001\/jama.2016.16951.","journal-title":"JAMA"},{"key":"1145_CR29","doi-asserted-by":"publisher","first-page":"4964262","DOI":"10.1155\/2022\/4964262","volume":"2022","author":"S Pu","year":"2022","unstructured":"Pu S, Jia C, Li Z, Zang Y. Protective mechanism of proprotein convertase subtilisin-like kexin type 9 inhibitor on rats with middle cerebral artery occlusion-induced cerebral ischemic infarction. Comput Intel Neurosc. 2022;2022:4964262. https:\/\/doi.org\/10.1155\/2022\/4964262.","journal-title":"Comput Intel Neurosc"},{"issue":"3\u20134","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000443770","volume":"3","author":"P Kumar","year":"2016","unstructured":"Kumar P, Misra S, Kumar A, Pandit AK, Chakravarty K, Prasad K. Association between tumor necrosis factor-alpha (-238G\/A and -308G\/A) gene polymorphisms and risk of ischemic stroke: a meta-analysis. Pulse (Basel). 2016;3(3\u20134):217\u201328. https:\/\/doi.org\/10.1159\/000443770.","journal-title":"Pulse (Basel)"},{"issue":"2","key":"1145_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118301","volume":"10","author":"LB Liu","year":"2015","unstructured":"Liu LB, Li M, Zhuo WY, Zhang YS, Xu AD. The role of hs-CRP, D-dimer and fibrinogen in differentiating etiological subtypes of ischemic stroke. PLoS ONE. 2015;10(2): e0118301. https:\/\/doi.org\/10.1371\/journal.pone.0118301.","journal-title":"PLoS ONE"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01145-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T14:53:50Z","timestamp":1737903230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01145-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,5]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01145-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,5]]},"assertion":[{"value":"26 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Dalian Medical Science Research Program (2023DF016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"The clinical data will be available at the ResMan website () within 5\u201324 months after the research results are published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (Approval number: YJ-KS-KY-2023-193) and performed in accordance with the tenets of the Declaration of Helsinki. The Data Monitoring Committee of the First Affiliated Hospital of Dalian Medical University monitored the progress of the trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Every patient recruited from six clinical centers provided written informed consent before participation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"W.T., H.C., X.L., and X.G.: data analysis, manuscript writing, and manuscript final editing. X.Y., D.L., X.J., Y.B., D.Z., X.L., P.X., J.L., and B.Z.: study design and data acquisition. H.D. and X.J.: study design, data analysis, manuscript final editing, and manuscript revision. All authors contributed to the article and approved the submitted version. X.J. acted as guarantor.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}